Nuvectis Pharma (NVCT) Share-based Compensation (2021 - 2026)

Nuvectis Pharma has disclosed Share-based Compensation across 6 years of filings, most recently posting $1.8 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $1.8 million, up 35.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.1 million (up 42.03% YoY), and the FY2025 annual result was $6.0 million, up 24.17% from the prior year.
• Share-based Compensation came in at $1.8 million for Q1 2026 at Nuvectis Pharma, up from $1.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $1.8 million in Q1 2026 to a low of $156000.0 in Q1 2022.
• The 5-year median for Share-based Compensation is $900000.0 (2025), against an average of $875941.2.
• Across the five-year window, Share-based Compensation sank 77.78% in 2022 and soared 798.72% in 2023, its largest moves.
• Nuvectis Pharma's Share-based Compensation stood at $482000.0 in 2022, then surged by 153.11% to $1.2 million in 2023, then declined by 6.48% to $1.1 million in 2024, then grew by 29.36% to $1.5 million in 2025, then rose by 25.34% to $1.8 million in 2026.
• The last three Share-based Compensation figures came in at $1.8 million (Q1 2026), $1.5 million (Q4 2025), and $900000.0 (Q3 2025), per Business Quant data.